Open Orphan PLC NEJM Opinion Piece
22 Julio 2021 - 1:00AM
RNS Non-Regulatory
TIDMORPH
Open Orphan PLC
22 July 2021
22 June 2021
OPEN ORPHAN PLC
("Open Orphan" or the "Company")
The New England Journal of Medicine (NEJM) publishes editorial
relating to
Human Challenge Programme
Open Orphan (AIM: ORPH), a rapidly growing specialist clinical
research organisation (CRO) and a world leader in vaccine and
antiviral testing using human challenge clinical trials, confirms
that an editorial opinion piece regarding the UK Government's Human
Challenge Programme has been published in the latest edition of the
New England Journal of Medicine (NEJM).
The piece, titled 'Establishing the Model during an Evolving
Pandemic', explores the extensive preliminary review process which
was commissioned by the UK Government and delivered by the
coalition involved in the COVID-19 Human Challenge Programme to
justify the research and manage and minimise the risks associated
with the trial, as well as arguments supporting the inclusion of a
SARS-CoV-2 human challenge research program as part of the pandemic
response.
The Human Challenge Programme, part of the UK Government's
Vaccine Taskforce, is a collaboration between the UK Government,
the Royal Free London NHS Foundation Trust, Imperial College London
and hVIVO , a subsidiary of Open Orphan, to deliver the world's
first human challenge study for COVID-19.
In human challenge studies, a small number of healthy volunteers
in a controlled setting are exposed to an infectious agent, in this
instance, COVID-19, for scientists and clinicians to assess how
effective vaccines or treatments are against the disease and
identify any side effects.
The NEJM is recognised as the world's leading medical journal
and website. Published continuously for over 200 years, the NEJM
delivers high-quality, peer-reviewed research and interactive
clinical content to physicians, educators, researchers, and the
global medical community. The publication's mission is to publish
the best research and information at the intersection of biomedical
science and clinical practice and to present this information in
understandable, clinically useful formats that inform health care
practice and improve patient outcomes.
Cathal Friel, Executive Chairman of Open Orphan plc, commented:
"We are delighted to see support for the COVID-19 Human Challenge
Programme in a publication such as the New England Journal of
Medicine. The piece articulates the considerable review process
commissioned by the UK Government and delivered by hVIVO, in
collaboration with the Royal Free London NHS Foundation Trust , and
Imperial College London. We believe the UK Government's COVID-19
Human Challenge Programme will play a vital role in trialling the
vaccines and antivirals which continue support our effective
pandemic response in the UK and abroad. "
For further information please contact:
Open Orphan plc +353 (0) 1 644 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser
and Joint Broker) +44 (0) 20 7614 5900
John Llewellyn-Lloyd / Richard Johnson
/ Oscair McGrath
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson/ Richard
Chambers
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780 or openorphan@walbrookpr.com
Paul McManus / Louis Ashe-Jepson +44 (0)7980 541 893 / 07747 515 393
/ Sam Allen / 07502 558 258
Notes to Editors
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing
pharmaceutical service/contract research company that is a world
leader in testing vaccines and antivirals using human challenge
clinical trials. The company provides services to Big Pharma,
biotech and government/public health organisations.
Open Orphan runs challenge studies in London from both its
19-bedroom Whitechapel quarantine clinic, opened in February 2021,
and its 24-bedroom QMB clinic with its highly specialised on-site
virology and immunology laboratory. Open Orphan has a leading
portfolio of eight human challenge study models for infectious and
respiratory diseases and is developing a number of other models
including the world's first COVID-19 human challenge study model as
part of the Human Challenge Programme .
Building upon its many years of challenge studies and virology
research, the Company is developing an in-depth database of
infectious disease progression data. Based on the Company's Disease
in Motion(R) platform, this unique dataset includes clinical,
immunological, virological and digital (wearable) biomarkers. The
Disease in Motion platform has many potential applications across a
wide variety of end users including big technology, wearables,
pharma and biotech companies. Following COVID-19 there is now a
renewed interest and investment in infectious diseases.
Open Orphan's Paris office has been providing biometry, data
management and statistics to its many European pharmaceutical
clients for over 20 years. For over 15 years, the Company's
Netherlands office has been providing drug development consultancy
and services, including CMC (chemistry, manufacturing and
controls), PK and medical writing, to a broad range of European
clients. Both offices are now also fully integrated with the London
office and working on challenge study contracts as well as
supporting third party trial contracts .
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRASEEEFFEFSEDW
(END) Dow Jones Newswires
July 22, 2021 02:00 ET (06:00 GMT)
Venn Life Sciences (LSE:VENN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Venn Life Sciences (LSE:VENN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024